PharmAbcine Inc. is a clinical stage public company developing next generation antibody therapeutics for oncology, ophthalmology (neovascular eye diseases including wAMD, DR/DME, glaucoma) and vascular-related diseases by utilizing its proprietary HuPhage Display Library platform.
Olinvacimab, anti-VEGFR2 neutralizing fully-human antibody, is our lead asset in Phase 2 stage for patients with mTNBC. Olinvacimab + Keytruda combination therapy in Phase 1b study for mTNBC patients delivered a clean safety profile with 50% ORR and 67% DCR.
PMC-403, anti-TIE2 agonizing mAb, normalizes leaky inflammatory pathological vasculature to healthy vasculature. Due to this MoA, IND for nAMD, DR/DME Phase 1 study has been submitted in December 2022.
PMC-309, anti-VISTA antagonizing mAb, can block negative immune checkpoint regulation by VISTA in pan-pH environment. IND submission for Phase 1 all-comers solid tumors will be submitted in Q2 of 2023.
Olinvacimab, anti-VEGFR2 neutralizing fully-human antibody, is our lead asset in Phase 2 stage for patients with mTNBC. Olinvacimab + Keytruda combination therapy in Phase 1b study for mTNBC patients delivered a clean safety profile with 50% ORR and 67% DCR.
PMC-403, anti-TIE2 agonizing mAb, normalizes leaky inflammatory pathological vasculature to healthy vasculature. Due to this MoA, IND for nAMD, DR/DME Phase 1 study has been submitted in December 2022.
PMC-309, anti-VISTA antagonizing mAb, can block negative immune checkpoint regulation by VISTA in pan-pH environment. IND submission for Phase 1 all-comers solid tumors will be submitted in Q2 of 2023.
Ticker:
208340 (KOSDAQ)
Exchange:
KOSDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Daejeon
Company HQ Country:
Korea, Republic of
Year Founded:
2008
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Olinvacimab
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8
Speaker
